Inventor
Eric L. Stangeland
Inventor
Pacifica, CA, US
Overview
Patents· 62 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%
C07DHeterocyclic compounds36%
A61KPreparations for medical, dental or toiletry purposes25%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
PatentTitleYear
10,946,0074-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds202110,865,201Bicyclic compounds useful as GPR120 modulators202010,836,744Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity202010,800,773Monocyclic compounds useful as GPR120 modulators202010,722,5044-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds202010,590,107Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity202010,441,5794-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds201910,358,433Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity201910,206,9134-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds201910,138,220Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity201810,034,8704-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds20189,975,875Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity20189,771,350'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,682,957'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,675,599'4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20179,572,802'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,260,414'Inhibitors of hepatitic C virus'20169,227,933'3-phenoxymethylpyrrolidine compounds'20169,187,423'Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20159,162,982'4-[2-(2-fluorophenoxy methyl)phenyl]piperidine compounds'20159,012,460'1-(2-phenoxymethylphenyl)piperazine compounds'20159,000,191'Serotonin reuptake inhibitors'20159,000,173'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20158,933,249'3-(phenoxyphenylmethyl)pyrrolidine compounds'20158,921,372'Inhibitors of hepatitis C virus'20148,853,255'3-phenoxymethylpyrrolidine compounds'20148,816,088'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20148,802,857'Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20148,778,949'1-(2-phenoxymethylphenyl)piperazine compounds'20148,729,119'Serotonin reuptake inhibitors'20148,637,568'Serotonin reuptake inhibitors'20148,618,131'Biphenyl derivatives'20138,604,058'4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20138,551,978'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20138,530,663'1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds'20138,501,776'Biphenyl compounds useful as muscarinic receptor antagonists'20138,501,964'Serotonin reuptake inhibitors'20138,471,040'Serotonin reuptake inhibitors'20138,455,665'3-phenoxymethylpyrrolidine compounds'20138,399,488'Biphenyl compounds useful as muscarinic receptor antagonists'20138,329,911'Biphenyl compounds useful as muscarinic receptor antagonists'20128,304,432'4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20128,273,786'3-phenoxymethylpyrrolidine compounds'20128,247,433'Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20128,242,164'3-(phenoxyphenylmethyl)pyrrolidine compounds'20128,242,135'Biphenyl derivatives'20128,138,345'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20128,119,796'Biphenyl compounds useful as muscarinic receptor antagonists'20128,067,439'Biphenyl compounds useful as muscarinic receptor antagonists'20118,013,152'Biphenyl compounds useful as muscarinic receptor antagonists'20117,888,386'3-(phenoxyphenylmethyl)pyrrolidine compounds'20117,879,879'Biphenyl derivatives'20117,868,175'Biphenyl compounds useful as muscarinic receptor antagonists'20117,851,631'Biphenyl compounds useful as muscarinic receptor antagonists'20107,728,144'Biphenyl compounds useful as muscarinic receptor antagonists'20107,683,173'Biphenyl compounds useful as muscarinic receptor antagonists'20107,642,355'Biphenyl compounds useful as muscarinic receptor antagonists'20107,629,336'Biphenyl compounds useful as muscarinic receptor antagonists'20097,514,558'Biphenyl derivatives'20097,479,562'Biphenyl compounds useful as muscarinic receptor antagonists'20097,262,205'Biphenyl compounds useful as muscarinic receptor antagonists'20077,141,671'Biphenyl derivatives'2006Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2006–2014Patents assigned to THERAVANCE INC (34)· patent assignee history
2006–2021Based in Pacifica, CA, US· patent location history
2011–2017Patents assigned to STANGELAND ERIC L (26)· patent assignee history
2012–2017Patents assigned to PATTERSON LORI JEAN (16)· patent assignee history
2012–2016Patents assigned to SAITO DAISUKE ROLAND (12)· patent assignee history
2014–2020Patents assigned to THERAVANCE RESPIRATORY CO LLC (10)· patent assignee history
2020Based in San Francisco, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| THERAVANCE INC | 34 | 2006–2014 |
| STANGELAND ERIC Lself | 26 | 2011–2017 |
| PATTERSON LORI JEAN | 16 | 2012–2017 |
| SAITO DAISUKE ROLAND | 12 | 2012–2016 |
| THERAVANCE RESPIRATORY CO LLC | 10 | 2014–2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pacifica, California, US | 60 | 2006–2021 |
| San Francisco, California, US | 2 | 2020 |